Table 2 ES of tanezumab on pain as measured by WOMAC Pain score based on bootstrap samples
ES, mean (95% CI) | Study 1 (vs. placebo) | Study 2 (vs. placebo) | Study 3 (vs. NSAID) | |||
|---|---|---|---|---|---|---|
Tanezumab 2.5 mg (N = 231) | Tanezumab 2.5/5 mg (N = 233) | Tanezumab 2.5 mg (N = 283) | Tanezumab 5 mg (N = 284) | Tanezumab 2.5 mg (N = 1002) | Tanezumab 5 mg (N = 998) | |
Pooled baseline SD | −0.416 (− 0.796, − 0.060) | −0.569 (− 0.952, − 0.179) | −0.547 (− 0.900, − 0.208) | −0.691 (− 1.06, − 0.352) | −0.167 (− 0.324, 0.001) | −0.255 (− 0.454, − 0.062) |
Pooled SD at the time when the primary endpoints were assessed* | −0.195 (− 0.371, − 0.028) | −0.267 (− 0.447, − 0.085) | −0.250 (− 0.403, − 0.095) | −0.316 (− 0.482, − 0.163) | −0.084 (− 0.163, 0.001) | −0.128 (− 0.228, − 0.032) |
Median of pooled SD from baseline to the time when the primary endpoints were assessed* | −0.196 (− 0.373, − 0.028) | −0.268 (− 0.444, − 0.085) | −0.256 (− 0.414, − 0.098) | −0.323 (− 0.492, − 0.165) | −0.085 (− 0.165, 0.001) | −0.129 (− 0.231, − 0.032) |